原发性宫颈恶性黑色素瘤诊疗进展研究
摘要
<正>原发性宫颈恶性黑色素瘤是一种极为罕见的恶性肿瘤,现有的临床资料十分有限,在诊断、治疗及预后等方面尚无系统指南及专家共识。本文对原发性宫颈恶性黑色素瘤治疗进展作一综述,旨在为临床诊治提供一定参考。
引文
[1] Yuan G,Wu L,Li B,et al. Primary malignant melanoma of the cervix:Report of 14 cases and review of literature[J]. Oncotarget,2017,8(42):73162-73167.
[2]王富强,谭改民.原发性子宫颈恶性黑色素瘤六例临床病理观察[J].中国实用医刊,2017,44(7):7-9.
[3] Min KJ,Kim YS,Hong JH,et al. Primary malignant melanoma of uterine cervix:a suggestion of new scheme of treatment combination[J]. Chin J Cancer Res,2014,26(3):351-354
[4]杨莉,吴小华,张志毅,等.原发性宫颈及阴道恶性黑色素瘤51例的临床分析[J].中国癌症杂志, 2013, 23(7):540-546.
[5] Nai GA,Bazan A,Rocha CA,et al. Postpartum genital melanomaa case report[J]. Rev Bras Ginecol Obstet, 2018, 40(3):163-167.
[6] Lim KH,Tay SK,Ng AX,et al. Primary melanoma of the uterine cervix:a case report,with key points on recognition and pathological diagnosis[J].J Low Genit Tract Dis,2017,21(1):e1-e4.
[7]丁匀浚毓,杨晓东,田园,等.原发性子宫颈恶性黑色素瘤1例分析[J].中国实验诊断学,2013,17(10):1919-1920.
[8] Zivadinovic R,Mijovic Z,Petric A,et al. Metastatic malignant melanoma of the uterus diagnosed by colposcopy[J]. Srp Arh Celok Lek,2016,144(5-6):329-333.
[9]段瑶,关铮,刘爱军.原发性宫颈恶性黑色素瘤4例临床病理分析及文献复习[J].国际妇产科学杂志,2015,42(4):477-480.
[10] Myriokefalitaki E,Babbel B,Smith M,et al. Primary malignant melanoma of uterine cervix FIGOⅡa1:A case report with 40months ongoing survival and literature review[J]. Gynecol Oncol Case Rep,2013,23(5):52-54.
[11]许峰,谭洁,汪娟.原发性子宫颈恶性黑色素瘤2例临床分析及文献复习[J].中国妇幼健康研究,2013,24(2):276-277.
[12] Ferraioli D,Lamblin G,Mathevet P,et al. Genital melanoma:prognosis factors and treatment modality[J]. Arch Gynecol Obstet,2016,294(5):1037-1045.
[13] Lee JH,Yun J,Seo JW,et al. Primary malignant melanoma of cervix and vagina[J]. Obstet Gynecol Sci, 2016, 59(5):415-420.
[14] Juliao I,Carvalho SD,Patricio V,et al. Primary malignant melanoma of the cervix:a rare disease[J]. BMJ Case Rep,2017.(published online)
[15] Arik D,Oge T,Kabukcuoglu S,et al. Amelanotic malignant melanoma of the uterine cervix diagnosed by cervical smear[J]. Diagn Cytopathol,2016,44(6):535-537.
[16]杜艳,赵华,范钦和,等.子宫颈原发性恶性黑色素瘤临床病理分析[J].中华病理学杂志,2014,43(9):625-626.
[17] Norris HJ,Taylor HB. Melanomas of the vagina[J]. Am J Clin Pathol,1966,46(4):420-426.
[18] Weissinger SE,Keil P,Silvers DN,et al. A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma[J]. Mod Pathol,2014,27(4):524-534.
[19]凌舸,王春萌.恶性黑色素瘤免疫治疗现状与进展[J].中国肿瘤,2018,27(1):54-60.
[20] Cetinkaya K,Benzer E,Dervisoglu H. Primary mucosal malignant melanoma of the cervix:case report and review of the literature[J].Tumori,2015,101(5):e147-150.
[21] Liu Z,Wang H,Zhang X,et al. Primary malignant melanoma of the cervix:A case report[J]. BMJ Case Rep,2014,8(6):2661-2663.
[22]唐碧霞,斯璐,迟志宏,等.替莫唑胺联合舒尼替尼治疗转移性黏膜黑色素瘤的疗效及安全性[J].中国肿瘤生物治疗杂志,2017,24(8):870-874.
[23] Strojan P,Jancar B,Cemazar M,et al. Melanoma metastases to the neck nodes:role of adjuvant irradiation[J]. Int J Radiat Oncol Biol Phys,2010,77(4):1039-1045.
[24]冯晨,童梅,林福玉,等.干扰素α1b对黑色素瘤细胞A375增殖、迁移和凋亡的影响[J].现代生物医学进展,2018,18(3):453-457.
[25] Mocellin S,Pasquali S,Rossi CR,et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma:a systematic review and meta-analysis[J].J Natl Cancer Inst,2010,102(7):493-501.
[26]金谷,夏李明,吴昊,等.恶性黑色素瘤大剂量干扰素辅助治疗诱导期的耐受性观察[J].肿瘤学杂志,2017,23(11):950-954.
[27]甄振华,申传厚.转移性恶性黑色素瘤分子靶向及免疫治疗进展[J].中国肿瘤,2014,23(10):854-859.
[28] Yamazaki N,Uhara H,Fukushima S,et al. PhaseⅡstudy of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma[J]. Cancer Chemother Pharmacol, 2015, 76(5):969-975.
[29] Robert C,Thomas L,Bondarenko I,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J]. N Engl J Med,2011,364(26):2517-2526.
[30] Geoerger B,Bergeron C,Gore L,et al. PhaseⅡstudy of ipilimumab in adolescents with unresectable stageⅢorⅣmalignant melanoma[J]. Eur J Cancer,2017,86:358-363.
[31] Weber J,Mandala M,Del Vecchio M,et al. Adjuvant nivolumab versus ipilimumab in resected stageⅢorⅣmelanoma[J]. N Engl J Med,2017,377(19):1824-1835.
[32] Zippel D,Markel G,Shapira-Frommer R,et al. Perioperative BRAF inhibitors in locally advanced stageⅢmelanoma[J]. J Surg Oncol,2017,116(7):856-861.
[33] Skinner CC,Mcmichael EL,Jaime-ramirez AC,et al. Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions[J].Melanoma Res,2016,26(4):329-337.
[34]李莹,王为光,王爱春,等. BRAF基因突变表达与人类恶性黑色素瘤易感病理亚型的Meta分析[J].黑龙江医药科学,2018,41(2):87-91.
[35] Vaysse C,Pautier P,Filleron T,et al. A large retrospective multicenter study of vaginal melanomas:implications for new management[J]. Melanoma Res,2013,23(2):138-146.
[36] Tarhini AA,Cherian J,Moschos SJ,et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stageⅣmelanoma[J]. J Clin Oncol,2012,30(3):322-328.
[37]薛金旭,宋建民,李晶,等.隔离热灌注化疗治疗肢体恶性黑色素瘤的临床研究[J].中华肿瘤防治杂志,2017,24(12):850-854.
[38] Eggermont AMM,Blank CU,Mandala M,et al. Adjuvant pembrolizumab versus placebo in resected stageⅢmelanoma[J]. N Engl J Med,2018,378(19):1789-1801.
[39] Read TA,Smith a,Thomas J,et al. Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective,non-randomized, single center study[J]. J Surg Oncol,2018,117(4):579-587.
[40] Nasarre P,Bonilla IV,Metcalf JS,et al. TRAF3-interacting protein 3,a new oncotarget,promotes tumor growth in melanoma[J].Melanoma Res,2018,28(3):185-194.
[41] Peng YG,Zhang L. Baohuoside-I suppresses cell proliferation and migration by up-regulating miR-144 in melanoma[J]. Pharm Biol,2018,56(1):43-50.
[42] Pusceddu S,Bajetta E,Carcangiu ML,et al. A literature overview of primary cervical malignant melanoma:an exceedingly rare cancer[J]. Crit Rev Oncol Hematol,2012,81(2):185-195.
[2]王富强,谭改民.原发性子宫颈恶性黑色素瘤六例临床病理观察[J].中国实用医刊,2017,44(7):7-9.
[3] Min KJ,Kim YS,Hong JH,et al. Primary malignant melanoma of uterine cervix:a suggestion of new scheme of treatment combination[J]. Chin J Cancer Res,2014,26(3):351-354
[4]杨莉,吴小华,张志毅,等.原发性宫颈及阴道恶性黑色素瘤51例的临床分析[J].中国癌症杂志, 2013, 23(7):540-546.
[5] Nai GA,Bazan A,Rocha CA,et al. Postpartum genital melanomaa case report[J]. Rev Bras Ginecol Obstet, 2018, 40(3):163-167.
[6] Lim KH,Tay SK,Ng AX,et al. Primary melanoma of the uterine cervix:a case report,with key points on recognition and pathological diagnosis[J].J Low Genit Tract Dis,2017,21(1):e1-e4.
[7]丁匀浚毓,杨晓东,田园,等.原发性子宫颈恶性黑色素瘤1例分析[J].中国实验诊断学,2013,17(10):1919-1920.
[8] Zivadinovic R,Mijovic Z,Petric A,et al. Metastatic malignant melanoma of the uterus diagnosed by colposcopy[J]. Srp Arh Celok Lek,2016,144(5-6):329-333.
[9]段瑶,关铮,刘爱军.原发性宫颈恶性黑色素瘤4例临床病理分析及文献复习[J].国际妇产科学杂志,2015,42(4):477-480.
[10] Myriokefalitaki E,Babbel B,Smith M,et al. Primary malignant melanoma of uterine cervix FIGOⅡa1:A case report with 40months ongoing survival and literature review[J]. Gynecol Oncol Case Rep,2013,23(5):52-54.
[11]许峰,谭洁,汪娟.原发性子宫颈恶性黑色素瘤2例临床分析及文献复习[J].中国妇幼健康研究,2013,24(2):276-277.
[12] Ferraioli D,Lamblin G,Mathevet P,et al. Genital melanoma:prognosis factors and treatment modality[J]. Arch Gynecol Obstet,2016,294(5):1037-1045.
[13] Lee JH,Yun J,Seo JW,et al. Primary malignant melanoma of cervix and vagina[J]. Obstet Gynecol Sci, 2016, 59(5):415-420.
[14] Juliao I,Carvalho SD,Patricio V,et al. Primary malignant melanoma of the cervix:a rare disease[J]. BMJ Case Rep,2017.(published online)
[15] Arik D,Oge T,Kabukcuoglu S,et al. Amelanotic malignant melanoma of the uterine cervix diagnosed by cervical smear[J]. Diagn Cytopathol,2016,44(6):535-537.
[16]杜艳,赵华,范钦和,等.子宫颈原发性恶性黑色素瘤临床病理分析[J].中华病理学杂志,2014,43(9):625-626.
[17] Norris HJ,Taylor HB. Melanomas of the vagina[J]. Am J Clin Pathol,1966,46(4):420-426.
[18] Weissinger SE,Keil P,Silvers DN,et al. A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma[J]. Mod Pathol,2014,27(4):524-534.
[19]凌舸,王春萌.恶性黑色素瘤免疫治疗现状与进展[J].中国肿瘤,2018,27(1):54-60.
[20] Cetinkaya K,Benzer E,Dervisoglu H. Primary mucosal malignant melanoma of the cervix:case report and review of the literature[J].Tumori,2015,101(5):e147-150.
[21] Liu Z,Wang H,Zhang X,et al. Primary malignant melanoma of the cervix:A case report[J]. BMJ Case Rep,2014,8(6):2661-2663.
[22]唐碧霞,斯璐,迟志宏,等.替莫唑胺联合舒尼替尼治疗转移性黏膜黑色素瘤的疗效及安全性[J].中国肿瘤生物治疗杂志,2017,24(8):870-874.
[23] Strojan P,Jancar B,Cemazar M,et al. Melanoma metastases to the neck nodes:role of adjuvant irradiation[J]. Int J Radiat Oncol Biol Phys,2010,77(4):1039-1045.
[24]冯晨,童梅,林福玉,等.干扰素α1b对黑色素瘤细胞A375增殖、迁移和凋亡的影响[J].现代生物医学进展,2018,18(3):453-457.
[25] Mocellin S,Pasquali S,Rossi CR,et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma:a systematic review and meta-analysis[J].J Natl Cancer Inst,2010,102(7):493-501.
[26]金谷,夏李明,吴昊,等.恶性黑色素瘤大剂量干扰素辅助治疗诱导期的耐受性观察[J].肿瘤学杂志,2017,23(11):950-954.
[27]甄振华,申传厚.转移性恶性黑色素瘤分子靶向及免疫治疗进展[J].中国肿瘤,2014,23(10):854-859.
[28] Yamazaki N,Uhara H,Fukushima S,et al. PhaseⅡstudy of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma[J]. Cancer Chemother Pharmacol, 2015, 76(5):969-975.
[29] Robert C,Thomas L,Bondarenko I,et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma[J]. N Engl J Med,2011,364(26):2517-2526.
[30] Geoerger B,Bergeron C,Gore L,et al. PhaseⅡstudy of ipilimumab in adolescents with unresectable stageⅢorⅣmalignant melanoma[J]. Eur J Cancer,2017,86:358-363.
[31] Weber J,Mandala M,Del Vecchio M,et al. Adjuvant nivolumab versus ipilimumab in resected stageⅢorⅣmelanoma[J]. N Engl J Med,2017,377(19):1824-1835.
[32] Zippel D,Markel G,Shapira-Frommer R,et al. Perioperative BRAF inhibitors in locally advanced stageⅢmelanoma[J]. J Surg Oncol,2017,116(7):856-861.
[33] Skinner CC,Mcmichael EL,Jaime-ramirez AC,et al. Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions[J].Melanoma Res,2016,26(4):329-337.
[34]李莹,王为光,王爱春,等. BRAF基因突变表达与人类恶性黑色素瘤易感病理亚型的Meta分析[J].黑龙江医药科学,2018,41(2):87-91.
[35] Vaysse C,Pautier P,Filleron T,et al. A large retrospective multicenter study of vaginal melanomas:implications for new management[J]. Melanoma Res,2013,23(2):138-146.
[36] Tarhini AA,Cherian J,Moschos SJ,et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stageⅣmelanoma[J]. J Clin Oncol,2012,30(3):322-328.
[37]薛金旭,宋建民,李晶,等.隔离热灌注化疗治疗肢体恶性黑色素瘤的临床研究[J].中华肿瘤防治杂志,2017,24(12):850-854.
[38] Eggermont AMM,Blank CU,Mandala M,et al. Adjuvant pembrolizumab versus placebo in resected stageⅢmelanoma[J]. N Engl J Med,2018,378(19):1789-1801.
[39] Read TA,Smith a,Thomas J,et al. Intralesional PV-10 for the treatment of in-transit melanoma metastases-Results of a prospective,non-randomized, single center study[J]. J Surg Oncol,2018,117(4):579-587.
[40] Nasarre P,Bonilla IV,Metcalf JS,et al. TRAF3-interacting protein 3,a new oncotarget,promotes tumor growth in melanoma[J].Melanoma Res,2018,28(3):185-194.
[41] Peng YG,Zhang L. Baohuoside-I suppresses cell proliferation and migration by up-regulating miR-144 in melanoma[J]. Pharm Biol,2018,56(1):43-50.
[42] Pusceddu S,Bajetta E,Carcangiu ML,et al. A literature overview of primary cervical malignant melanoma:an exceedingly rare cancer[J]. Crit Rev Oncol Hematol,2012,81(2):185-195.